Comparative effectiveness of traditional chemoembolization with or without sorafenib for hepatocellular carcinoma

Table 3 Comparison of demographic and disease characteristics of patients with hepatocellular carcinoma in both treatment groups

Characteristic	TACE + sorafenib(n = 13)	TACE alone(n = 30)	P value
Age (yr)	61.4 ± 7.5	59.2 ± 7.4	0.39
Etiology			0.18
Alcohol	2 (15.4)	1 (3.4)
Hepatitis C	6 (46.1)	17 (56.6)
Hepatitis C and alcohol	3 (23.1)	11 (36.6)
Non-alcohol/non-hepatitis C	2 (15.4)	1 (3.4)
HCC histology			0.86
Poorly differentiated	1 (7.6)	3 (10.0)
Moderately differentiated	7 (53.8)	13 (43.3)
Well differentiated	5 (38.6)	14 (46.7)
CTP classification			0.69
A	11	23
B	2	7
BCLC staging for HCC			0.004
A	6	22
B	2	8
C	5	0
BCLC staging for HCC (excluding stage C)			0.98
A	6	22
B	2	8
MELD score	8.8 ± 2.3	9.8 ± 2.9	0.29
AFP (ng/mL)	6.6 (2.3-745)	8.1 (1.9-6000)	0.96
Tumor size seen on CT with the largest diameter (cm)	4 (1.5 -16.7)	3.1 (1.4 -5.8)	0.58

Data are summarized as the mean ± SD or median (range). HCC: Hepatocellular carcinoma; TACE: Transarterial chemoembolization; CTP: Child-Turcotte-Pugh; BCLC: Barcelona Clinic Liver Cancer; MELD: Model of end stage liver disease; AFP: Alpha fetoprotein; CT: Computed tomography.